1. A phase 1/2, open-label, multicenter study to investigate the safety, pharmacokinetics, and efficacy of fadraciclib (CYC065), an oral CDK2/9 inhibitor, in subjects with advanced solid tumors and lymphoma. (October 2022) Authors: Piha-Paul, S.; Oh, D.Y.; Garralda, E.; Vieito, M.; Huang, J.; Kirschbaum, M.; Villanona-Calero, M. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S17 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Light‐controllable polymeric material based on temperature‐sensitive hydrogels with incorporated graphene oxide (Phys. Status Solidi A 6∕2015). Issue 6 (June 2015) Authors: Breuer, L.; Raue, M.; Kirschbaum, M.; Mang, T.; Schöning, M. J.; Thoelen, R.; Wagner, T. Journal: Physica status solidi Issue: Volume 212:Issue 6(2015:Jun.) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Light‐controllable polymeric material based on temperature‐sensitive hydrogels with incorporated graphene oxide. Issue 6 (24th March 2015) Authors: Breuer, L.; Raue, M.; Kirschbaum, M.; Mang, T.; Schöning, M. J.; Thoelen, R.; Wagner, T. Journal: Physica status solidi Issue: Volume 212:Issue 6(2015:Jun.) Page Start: 1368 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗